Meng Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meng Zhao has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Haojin Zhou
Wisdom Lake Academy of Pharmacy
2 shared publications- Jiaqi Wang
Department of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Pokfulam Road, Hong Kong SAR 999077, P. R. China
2 shared publications Shujia Liu
Wisdom Lake Academy of Pharmacy
2 shared publications- Chang-Nan Wang
Lab of Stress Injury, School of Life Sciences, Shanghai University, Shanghai 200444, China
1 shared publication - Hongming Zhu
Institute for Regenerative Medicine & Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
1 shared publication - Jian Wang
Department of Emergency, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 6 December 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1)
Protective effects of biomimetic Cu-Zn-MOF against DOX-Induced cardiotoxicity through inhibiting oxidative stress and ferroptosis
Doxorubicin (DOX), a member of the anthracycline family, is widely recognized as an effective chemotherapeutic agent for cancer treatment. However, its cli
- 6 December 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1)
Open AccessProtective effects of biomimetic Cu-Zn-MOF against DOX-Induced cardiotoxicity through inhibiting oxidative stress and ferroptosis
Doxorubicin (DOX), a member of the anthracycline family, is widely recognized as an effective chemotherapeutic agent for cancer treatment. However, its cli
- Open Access
- 17 October 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (42) , 50088-50102
Computational Discovery of Aggregation-Mediated Dipeptide Inhibitors Targeting PHLDA1 for Cardiovascular Therapy
Cardiovascular disease remains a leading cause of global mortality, underscoring the urgent need for novel therapeutic strategies. This study focuses on the pleckstrin homology-like domain family A member 1-encoded protein (PEP), a regulator of cardiomyocyte apoptosis and a promising yet underexplored therapeutic target. Leveraging an integrated computational approach, we combined AlphaFold3-based structure prediction with extensive molecular dynamics simulations to characterize PEP's dynamic architecture and identify high-affinity dipeptide inhibitors. Our results reveal that PEP possesses significant intrinsic disorder, with molecular dynamics simulations refining its conformation and highlighting force field-dependent behaviors, particularly the superior performance of CHARMM-class force fields in preserving functional secondary structures. High-throughput screening of phenylalanine-based dipeptides identified FF as the strongest binder, exhibiting a unique aggregation-mediated binding mechanism that engages both primary and secondary sites on PEP through multivalent interactions. Concentration-dependent simulations further confirmed the robustness of FF binding and revealed residue-specific interaction hotspots. Notably, we demonstrate that low-confidence regions in AF3 predictions (pLDDT <50) frequently participate in functional binding, challenging the conventional lock-and-key paradigm. These findings not only establish PEP as a tractable drug target but also provide a novel framework for designing aggregation-prone peptide therapeutics against cardiovascular diseases.
- 17 October 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (42) , 50088-50102
Open AccessComputational Discovery of Aggregation-Mediated Dipeptide Inhibitors Targeting PHLDA1 for Cardiovascular Therapy
Cardiovascular disease remains a leading cause of global mortality, underscoring the urgent need for novel therapeutic strategies. This study focuses on the pleckstrin homology-like domain family A member 1-encoded protein (PEP), a regulator of cardiomyocyte apoptosis and a promising yet underexplored therapeutic target. Leveraging an integrated computational approach, we combined AlphaFold3-based structure prediction with extensive molecular dynamics simulations to characterize PEP's dynamic architecture and identify high-affinity dipeptide inhibitors. Our results reveal that PEP possesses significant intrinsic disorder, with molecular dynamics simulations refining its conformation and highlighting force field-dependent behaviors, particularly the superior performance of CHARMM-class force fields in preserving functional secondary structures. High-throughput screening of phenylalanine-based dipeptides identified FF as the strongest binder, exhibiting a unique aggregation-mediated binding mechanism that engages both primary and secondary sites on PEP through multivalent interactions. Concentration-dependent simulations further confirmed the robustness of FF binding and revealed residue-specific interaction hotspots. Notably, we demonstrate that low-confidence regions in AF3 predictions (pLDDT <50) frequently participate in functional binding, challenging the conventional lock-and-key paradigm. These findings not only establish PEP as a tractable drug target but also provide a novel framework for designing aggregation-prone peptide therapeutics against cardiovascular diseases.
- Open Access
In Silico Screening of Peptide Inhibitors of PHLDA1-Encoded Protein Targeting Cardiovascular Diseases
The PHLDA1-encoded protein (PEP) is a pivotal regulator of cardiomyocyte apoptosis and a promising therapeutic target for cardiovascular diseases. Leveraging in silico approaches, we characterized PEP's structure using AlphaFold3 (AF3) and refined it via molecular dynamics (MD) simulations with various force fields. Kinetic and thermodynamics analysis further confirmed revealed that the Amber99 force field induced the most significant structural change, with the most significant decrease in radius of gyration and lowest potential energy. High-throughput screening of 20 phenylalanine-based dipeptides (FA-FY) revealed sequence-dependent binding to PEP, with FF, FH, FP, and FY exhibiting the maximum count of binders (11, 7, 6, and 6, respectively). Key residues (e.g., L55, C60, E142, E89) formed a continuous binding groove, while FF dipeptides demonstrated cooperative aggregation-enhanced binding. Notably, low-pLDDT regions (< 50) frequently participated in ligand interactions, challenging the rigid "lock-and-key" paradigm and underscoring the role of intrinsic disorder in binding. this work establishes PEP as a tractable target for dipeptide inhibitors and provides a computational framework for designing peptide-based therapeutics against cardiac injury.
Open AccessIn Silico Screening of Peptide Inhibitors of PHLDA1-Encoded Protein Targeting Cardiovascular Diseases
The PHLDA1-encoded protein (PEP) is a pivotal regulator of cardiomyocyte apoptosis and a promising therapeutic target for cardiovascular diseases. Leveraging in silico approaches, we characterized PEP's structure using AlphaFold3 (AF3) and refined it via molecular dynamics (MD) simulations with various force fields. Kinetic and thermodynamics analysis further confirmed revealed that the Amber99 force field induced the most significant structural change, with the most significant decrease in radius of gyration and lowest potential energy. High-throughput screening of 20 phenylalanine-based dipeptides (FA-FY) revealed sequence-dependent binding to PEP, with FF, FH, FP, and FY exhibiting the maximum count of binders (11, 7, 6, and 6, respectively). Key residues (e.g., L55, C60, E142, E89) formed a continuous binding groove, while FF dipeptides demonstrated cooperative aggregation-enhanced binding. Notably, low-pLDDT regions (< 50) frequently participated in ligand interactions, challenging the rigid "lock-and-key" paradigm and underscoring the role of intrinsic disorder in binding. this work establishes PEP as a tractable target for dipeptide inhibitors and provides a computational framework for designing peptide-based therapeutics against cardiac injury.